Advanced

Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis

Olsson, Rolf; Mattsson, Lars-Åke; Obrant, Karl LU and Mellstrom, Dan (1999) In Liver 19(3). p.188-192
Abstract
AIMS/BACKGROUND: Patients with primary biliary cirrhosis (PBC) often have osteoporosis of the high-turnover type, suggesting that estrogen could have a beneficial effect. However, the cholestatic potential of estrogen could imply a risk of increased cholestasis in a disease characterized by cholestasis. The aim of the present study was to test whether hormone replacement therapy (HRT) could be used to increase bone mineral density (BMD) in PBC patients with osteoporosis, without causing deterioration of the liver function. METHODS: Nine female PBC patients with osteoporosis and one with osteopenia were offered HRT for two years. The change in BMD was compared to the change in ten age-matched female PBC patients who had less severe or no... (More)
AIMS/BACKGROUND: Patients with primary biliary cirrhosis (PBC) often have osteoporosis of the high-turnover type, suggesting that estrogen could have a beneficial effect. However, the cholestatic potential of estrogen could imply a risk of increased cholestasis in a disease characterized by cholestasis. The aim of the present study was to test whether hormone replacement therapy (HRT) could be used to increase bone mineral density (BMD) in PBC patients with osteoporosis, without causing deterioration of the liver function. METHODS: Nine female PBC patients with osteoporosis and one with osteopenia were offered HRT for two years. The change in BMD was compared to the change in ten age-matched female PBC patients who had less severe or no osteopenia and who did not receive HRT. Liver function tests were checked at six-month intervals. RESULTS: HRT patients showed a statistically significant increase in lumbar spine BMD and total body BMD whereas control patients showed a significant decrease in lumbar and total body BMD. In contrast to the controls, HRT patients also showed a decrease in truncal fat (-3.8%). Neither of the groups showed any statistically significant changes in the liver function tests. CONCLUSIONS: HRT is safe and effective in female PBC patients with osteoporosis. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
primary biliary cirrhosis, osteoporosis, estrogen treatment, bone mineral density, liver function tests
in
Liver
volume
19
issue
3
pages
188 - 192
publisher
Munksgaard International Publishers
external identifiers
  • pmid:10395037
  • scopus:0032979475
ISSN
0106-9543
DOI
10.1111/j.1478-3231.1999.tb00034.x
language
English
LU publication?
yes
id
a51487a7-47c3-4ed6-bd7a-124bb9340137 (old id 1114948)
date added to LUP
2008-07-07 11:26:55
date last changed
2017-01-01 04:35:13
@article{a51487a7-47c3-4ed6-bd7a-124bb9340137,
  abstract     = {AIMS/BACKGROUND: Patients with primary biliary cirrhosis (PBC) often have osteoporosis of the high-turnover type, suggesting that estrogen could have a beneficial effect. However, the cholestatic potential of estrogen could imply a risk of increased cholestasis in a disease characterized by cholestasis. The aim of the present study was to test whether hormone replacement therapy (HRT) could be used to increase bone mineral density (BMD) in PBC patients with osteoporosis, without causing deterioration of the liver function. METHODS: Nine female PBC patients with osteoporosis and one with osteopenia were offered HRT for two years. The change in BMD was compared to the change in ten age-matched female PBC patients who had less severe or no osteopenia and who did not receive HRT. Liver function tests were checked at six-month intervals. RESULTS: HRT patients showed a statistically significant increase in lumbar spine BMD and total body BMD whereas control patients showed a significant decrease in lumbar and total body BMD. In contrast to the controls, HRT patients also showed a decrease in truncal fat (-3.8%). Neither of the groups showed any statistically significant changes in the liver function tests. CONCLUSIONS: HRT is safe and effective in female PBC patients with osteoporosis.},
  author       = {Olsson, Rolf and Mattsson, Lars-Åke and Obrant, Karl and Mellstrom, Dan},
  issn         = {0106-9543},
  keyword      = {primary biliary cirrhosis,osteoporosis,estrogen treatment,bone mineral density,liver function tests},
  language     = {eng},
  number       = {3},
  pages        = {188--192},
  publisher    = {Munksgaard International Publishers},
  series       = {Liver},
  title        = {Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis},
  url          = {http://dx.doi.org/10.1111/j.1478-3231.1999.tb00034.x},
  volume       = {19},
  year         = {1999},
}